Literature DB >> 9250552

Fentanyl pharmacokinetics in patients undergoing renal transplantation.

D E Koehntop1, J H Rodman.   

Abstract

STUDY
OBJECTIVE: To describe the pharmacokinetics of fentanyl in patients undergoing renal transplantation.
DESIGN: Prospective.
SETTING: A large university teaching hospital. PATIENTS: Eight patients (mean +/- SD age 35.5 +/- 11.5 yrs, weight 73.4 +/- 24.8 kg) with end-stage renal failure receiving kidneys from a living relative; three patients were never dialyzed, three were receiving peritoneal dialysis, and two were receiving hemodialysis.
INTERVENTIONS: Plasma was sampled before and at intervals up to 8 hours after intravenous injection of fentanyl 25 microg/kg before skin incision.
MEASUREMENTS AND MAIN RESULTS: Mean +/- SD (range) preoperative values were blood urea nitrogen (BUN) 66 +/- 30 (35-111) mg/dl; albumin 3.6 +/- 0.7 (2.6-4.5) g/dl; and triglycerides 414 +/- 352 (156-1270) mg/dl. Elimination half-life was 382 +/- 205 minutes; volume of distribution for the central compartment 0.74 +/- 0.48 L/kg; volume of distribution at steady state (Vd(ss)) 3.1 +/- 2.0 L/kg; total body clearance 7.5 +/- 5.1 ml x kg(-1) x min(-1). A significant inverse relationship between degree of azotemia and fentanyl clearance was found. The two patients with the highest preoperative BUNs had the lowest multiple of clearance and Vd(ss), and were also the only ones to require postoperative mechanical ventilation.
CONCLUSION: Although all patients received a kidney that functioned well after revascularization, the large intersubject variability in fentanyl kinetics may, in part, reflect their heterogeneity in dialysis status and renal failure-induced abnormalities. Marked decreases in fentanyl clearance do occur in these patients, appear to be related to very high BUN concentrations, and can lead to prolonged postoperative ventilatory depression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250552

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  12 in total

Review 1.  Strong opioids in pediatric palliative medicine.

Authors:  Richard D W Hain; Angela Miser; Mary Devins; W Hamish B Wallace
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Bioequivalence criteria for transdermal fentanyl generics: do these need a relook?

Authors:  Carmen Walter; Lisa Felden; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  Safety of chronic transdermal fentanyl use in patients receiving hemodialysis.

Authors:  Jin Han; Santosh L Saraf; Victor R Gordeuk; Michel Gowhari
Journal:  Am J Health Syst Pharm       Date:  2016-07-01       Impact factor: 2.637

Review 5.  Pain Management in Pediatric Chronic Kidney Disease.

Authors:  Amanda Reis; Caitlyn Luecke; Thomas Keefe Davis; Aadil Kakajiwala
Journal:  J Pediatr Pharmacol Ther       Date:  2018 May-Jun

Review 6.  A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.

Authors:  Evelien J M Kuip; Maarten L Zandvliet; Stijn L W Koolen; Ron H J Mathijssen; Carin C D van der Rijt
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

Review 7.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

9.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

10.  Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease.

Authors:  James B Wetmore; Mike Broce; Amer Malas; Ammar Almehmi
Journal:  Nephron Clin Pract       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.